A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025.

Tagrisso (osimertinib) - AstraZeneca

bozitinib (APL-101) - Apollomics

Tabrecta (capmatinib) - Novartis

Haiyitan (gumarontinib) - HaiHe Biopharma

Tepmetko (tepotinib) - EMD Serono

Orpathys (savolitinib) - AstraZeneca, Hutchmed

http://www.ncbi.nlm.nih.gov/pubmed/41195443

Sai-Hong Ignatius Ou; Yanyan Hu

Nov 6, 2025